Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 566 people with ankylosing spondylitis (a type of inflammatory arthritis that mainly affects the spine). Participants were split into two groups: 379 received etanercept and 187 received sulphasalazine, both existing medicines used for this condition. The trial's main goal was to measure how many people in each group achieved a recognised level of symptom improvement, known as "ASAS 20" — meaning at least a 20% improvement across key areas such as pain, physical function, and overall disease activity, rated on a 0–100 scale. The reported data shows that, for the primary measure, 287 out of 379 participants in the etanercept group and 99 out of 187 participants in the sulphasalazine group reached the ASAS 20 level of improvement. The trial also measured quality of life using a questionnaire called ASQoL, where scores range from 0 (better quality of life) to 18 (worse quality of life). The reported data shows that the etanercept group started with an average score of around 11.03 and this changed to 6.21 by the end of the study period, while the sulphasalazine group started at around 11.32 and reached 9.06. It should be noted that the exact timing of these follow-up scores was not fully detailed in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38488976) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Ankylosing Spondylitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed by a doctor with a condition called ankylosing spondylitis (a type of inflammatory arthritis that mainly affects the spine)
- Your ankylosing spondylitis is currently active (meaning you are experiencing ongoing symptoms)
Who may not be able to join:
- Your spine has become completely fused or locked together due to your condition
- You have previously been treated with a medication called etanercept (also known by the brand name Enbrel)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.